Demographic characteristics of study participants
. | Age . | Race . | Severity . | Product . | Prophylaxis . |
---|---|---|---|---|---|
Patient 1 | 3 y | African American | Severe | EHL | Yes |
Patient 2 | 17 mo | African American | Severe | EHL | Yes |
Patient 3 | 13 y | Caucasian | Mild | SHL | No |
Patient 4 | 10 y | Caucasian | Mild | SHL | No |
Patient 5 | 10 y | Caucasian | Mild | SHL | No |
Patient 6 | 2 y | Caucasian | Severe | SHL | Yes |
Patient 7 | 2 mo | Caucasian | Mild | None | N/A |
Patient 8 | 16 y | African American | Severe | EHL | Yes |
Patient 9 | 17 mo | African American | Severe | EHL | Yes |
Patient 10 | 15 y | Caucasian | Severe | EHL | Yes |
Patient 11 | 17 y | African American | Moderate | EHL | Yes |
. | Age . | Race . | Severity . | Product . | Prophylaxis . |
---|---|---|---|---|---|
Patient 1 | 3 y | African American | Severe | EHL | Yes |
Patient 2 | 17 mo | African American | Severe | EHL | Yes |
Patient 3 | 13 y | Caucasian | Mild | SHL | No |
Patient 4 | 10 y | Caucasian | Mild | SHL | No |
Patient 5 | 10 y | Caucasian | Mild | SHL | No |
Patient 6 | 2 y | Caucasian | Severe | SHL | Yes |
Patient 7 | 2 mo | Caucasian | Mild | None | N/A |
Patient 8 | 16 y | African American | Severe | EHL | Yes |
Patient 9 | 17 mo | African American | Severe | EHL | Yes |
Patient 10 | 15 y | Caucasian | Severe | EHL | Yes |
Patient 11 | 17 y | African American | Moderate | EHL | Yes |